• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Elise Mak

Articles by Elise Mak

Luye Pharma buys rights to Astrazeneca's antipsychotic Seroquel franchise for $546M

May 9, 2018
By Elise Mak
HONG KONG – China's Luye Pharma Group Ltd. acquired the rights of Astrazeneca plc's antipsychotics Seroquel (quetiapine fumarate) and Seroquel XR. The transaction, which will allow Luye to manufacture the drugs and market them in 51 countries and regions, is a win-win, helping Luye tap into the global market while Astrazeneca seeks to spin off products that are no longer part of its core business.
Read More

Luye Pharma buys rights to Astrazeneca's antipsychotic Seroquel franchise for $546M

May 8, 2018
By Elise Mak

HONG KONG – China's Luye Pharma Group Ltd. acquired the rights of Astrazeneca plc's antipsychotics Seroquel (quetiapine fumarate) and Seroquel XR. The transaction, which will allow Luye to manufacture the drugs and market them in 51 countries and regions, is a win-win, helping Luye tap into the global market while Astrazeneca seeks to spin off products that are no longer part of its core business.


Read More

South Korea's pricing policies could put pressure on novel drugs

May 4, 2018
By Elise Mak
HONG KONG – While the South Korean government's pricing regime is helping to make drugs more affordable in the country, it is also slowing the value growth of the pharmaceutical market and pressuring the sales of innovative drugs.
Read More

CBT, Crystalgenomics to collaborate on cancer combination therapy

May 2, 2018
By Elise Mak
HONG KONG – Sino-American biopharma company CBT Pharmaceuticals Inc. is set to work with South Korea's Crystalgenomics Inc. on an investigational combination therapy for solid tumors. The two agreed to co-develop and commercialize the final product worldwide.
Read More

Peptron taking GLP-1 agonist into neurodegenerative trials under NIH licensing deal

May 1, 2018
By Elise Mak

HONG KONG – South Korea's Peptron Inc. is looking to advance the development of sustained-release (SR) drugs, tapping into a global licensing deal with the U.S. NIH and focusing on developing new treatments for neurodegenerative disorders.


Read More

CBT, Crystalgenomics to collaborate on cancer combination therapy

April 30, 2018
By Elise Mak
HONG KONG – Sino-American biopharma company CBT Pharmaceuticals Inc. is set to work with South Korea's Crystalgenomics Inc. on an investigational combination therapy for solid tumors. The two agreed to co-develop and commercialize the final product worldwide.
Read More

Peptron taking GLP-1 agonist into neurodegenerative trials under NIH licensing deal

April 30, 2018
By Elise Mak
HONG KONG – South Korea's Peptron Inc. is looking to advance the development of sustained-release (SR) drugs, tapping into a global licensing deal with the U.S. NIH and focusing on developing new treatments for neurodegenerative disorders.
Read More

Wanted: More biotech listings for Hong Kong as new rules set to go into effect next week

April 26, 2018
By Cornelia Zou and Elise Mak
HONG KONG – Emerging biotech companies can start submitting their formal listing applications in Hong Kong next month as the Stock Exchange of Hong Kong (HKEX) said that proposed new rules to broaden its listing regime will come into effect on April 30.
Read More

PolyU invents lens to slow myopic progression in children

April 25, 2018
By Elise Mak

Alphamab's bispecific antibody gets clinical approval in China

April 25, 2018
By Elise Mak
HONG KONG – China's Suzhou Alphamab Co. Ltd. has obtained the IND approval from regulators for its HER2 bispecific antibody, KN-026. The phase I trials will commence later this year.
Read More
Previous 1 2 … 75 76 77 78 79 80 81 82 83 84 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 8, 2025.
  • Kidney disease illustration

    Prokidney produces positive phase II CKD data, thunderous stock surge

    BioWorld
    A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) and diabetes therapy, rilparencel....
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe